<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The role of plasminogen (Plg) and alpha2-antiplasmin (alpha2-AP) in vascular thrombolysis in vivo was investigated in mice deficient in plasminogen (Plg-/-) or a2-AP (alpha2-AP-/-) or their <z:mp ids='MP_0002169'>wild type</z:mp> (PAI-1+/+, alpha2-AP+/+) </plain></SENT>
<SENT sid="1" pm="."><plain>A <z:e sem="disease" ids="C0302148,C0087086" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">thrombus</z:e> was induced in the murine carotid artery or the internal jugular vein by endothelial injury </plain></SENT>
<SENT sid="2" pm="."><plain>Blood flow was continuously monitored for 90 min and for 6 h 30 min after the initiation of endothelial injury </plain></SENT>
<SENT sid="3" pm="."><plain>The times to occlusion by the developing <z:e sem="disease" ids="C0302148,C0087086" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">thrombus</z:e> in the carotid artery and the jugular vein of <z:mp ids='MP_0002169'>wild type</z:mp> mice were 12+/-1.8 and 7.2+/-1.9 min, respectively </plain></SENT>
<SENT sid="4" pm="."><plain>The arterial <z:e sem="disease" ids="C0302148,C0087086" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">thrombus</z:e> formation in alpha2-AP-/- mice was indistinguishable from the one in <z:mp ids='MP_0002169'>wild type</z:mp> mice, whereas the time to occlusion in Plg-/- was significantly shortened to 5.9+/-1.7 min </plain></SENT>
<SENT sid="5" pm="."><plain>Vascular patency after spontaneous reperfusion was markedly improved in alpha2-AP-/- mice </plain></SENT>
<SENT sid="6" pm="."><plain>On the contrary, arteriarpatency in Plg-/- mice was aggravated </plain></SENT>
<SENT sid="7" pm="."><plain>In venous <z:e sem="disease" ids="C0302148,C0087086" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">thrombus</z:e> formation, the time to occlusion in alpha2-AP-/- mice was significantly prolonged (27.1+/-5.2 min), whereas in Plg-/- it was slightly shortened to 6.5+/-2.5 min </plain></SENT>
<SENT sid="8" pm="."><plain>Vascular patency after spontaneous reperfusion was also improved in alpha2-AP-/- mice, but not in Plg-/- mice </plain></SENT>
<SENT sid="9" pm="."><plain>Histological observations using <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">SEM</z:e> indicated that fibrin nets were firmly fixed on the injured area in Plg-/- mice, but not in alpha2-AP-/- mice </plain></SENT>
<SENT sid="10" pm="."><plain>The tail <z:mp ids='MP_0001914'>bleeding</z:mp> time was not different in any type of mice </plain></SENT>
<SENT sid="11" pm="."><plain>However, re-<z:mp ids='MP_0001914'>bleeding</z:mp> time using a template <z:mp ids='MP_0001914'>bleeding</z:mp> device was significantly prolonged in alpha2-AP-/- as compared with that of <z:mp ids='MP_0002169'>wild type</z:mp> mice </plain></SENT>
<SENT sid="12" pm="."><plain>In conclusion, lack of plasminogen markedly reduces the antithrombotic activities in vivo, whereas alpha2-AP plays a more important role in the formation and removal of venous <z:e sem="disease" ids="C0302148,C0087086" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">thrombus</z:e> in mice </plain></SENT>
<SENT sid="13" pm="."><plain>Consequently, the inhibition of alpha2-AP could be a useful tool for the therapy of <z:hpo ids='HP_0004936'>venous thrombosis</z:hpo> and the prevention of re-<z:e sem="disease" ids="C0302148,C0087086" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">thrombus</z:e> formation </plain></SENT>
</text></document>